We are live on ! Find out more
FCMI

Foresite Capital Management II Portfolio holdings

AUM $29.2M
1-Year Est. Return 44.84%
This Fund
S&P 500
This Quarter Est. Return
-6.9%
1 Year Est. Return
+44.84%
3 Year Est. Return
-66.21%
5 Year Est. Return
-36.36%
10 Year Est. Return
–
AUM
$473M
AUM Growth
+$295M
Cap. Flow
+$357M
Cap. Flow %
75.38%
Top 10 Hldgs %
100%
Holding
8
New
1
Increased
–
Reduced
3
Closed
1

Top Buys

Rank Stock Value
1
TXG icon
10x Genomics
TXG
+$378M

Top Sells

Rank Stock Value
1
ALDR
Alder Biopharmaceuticals
ALDR
+$16.5M
2
AIMT
Aimmune Therapeutics
AIMT
+$2.47M
3
TWST icon
Twist Bioscience
TWST
+$2.11M
4
INSM icon
Insmed
INSM
+$781K

Sector Composition

Rank Sector Weight
1 Healthcare 81.67%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TXG icon
1
10x Genomics
TXG
$5.86B
$345M 72.85%
+6,837,253
New +$378M
AIMT
2
DELISTED
Aimmune Therapeutics
AIMT
$54.6M 11.53%
2,605,499
-121,069
-4% -$2.47M
AERI
3
DELISTED
Aerie Pharmaceuticals
AERI
$32.1M 6.8%
1,672,714
– –
INSM icon
4
Insmed
INSM
$23.1B
$16.1M 3.41%
915,016
-40,446
-4% -$781K
EPZM
5
DELISTED
Epizyme, Inc
EPZM
$15.4M 3.25%
1,488,444
– –
XLRN
6
DELISTED
Acceleron Pharma
XLRN
$7.45M 1.58%
188,602
– –
ALDR
7
DELISTED
Alder Biopharmaceuticals
ALDR
$2.77M 0.59%
146,800
-1,439,420
-91% -$16.5M
TWST icon
8
Twist Bioscience
TWST
$5.39B
– –
-72,849
Closed -$2.11M

Similar funds

AG
Appleton Group Appleton, Wisconsin $28.6M AUM 32.21% 1-Year Est. Return
SAM
Sandbar Asset Management London, United Kingdom $30.5M AUM 46.07% 1-Year Est. Return
AC
Amia Capital London, United Kingdom $32.1M AUM 0.56% 1-Year Est. Return
QI
Qualcomm Inc San Diego, California $32.1M AUM 5.35% 1-Year Est. Return
TAAM
Top Ace Asset Management Hong Kong $25.3M AUM 23.27% 1-Year Est. Return
NAM
Nationwide Asset Management Columbus, Ohio $25.1M AUM 13.37% 1-Year Est. Return
MSKCC
Memorial Sloan Kettering Cancer Center New York $24.6M AUM 10.16% 1-Year Est. Return
BRC
Bishop Rock Capital New York $24.3M AUM 20.73% 1-Year Est. Return

Foresite Capital Management II's Q3 2019 Portfolio in Review

As of Q3 2019, Foresite Capital Management II held 8 positions worth $473M, up 166% from $178M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Foresite Capital Management II deployed $357M of net new capital in Q3 2019, opening 1 new position. Its largest new stake was 10x Genomics: 6,837,253 shares worth $345M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 40% a quarter earlier.

On the sell side, the largest reduction was Alder Biopharmaceuticals, an estimated $16.5M trimmed.

  • Foresite Capital Management II's largest Q3 2019 buy was 10x Genomics: 6,837,253 shares worth $345M.
  • Foresite Capital Management II's biggest Q3 2019 reduction was Alder Biopharmaceuticals, cutting an estimated $16.5M.
  • Foresite Capital Management II fully exited Twist Bioscience in Q3 2019, selling an estimated $2.11M.
  • Foresite Capital Management II's ten largest holdings make up 100% of its $473M portfolio in Q3 2019.
  • Foresite Capital Management II opened 1 new position and closed 1 in Q3 2019.
  • Foresite Capital Management II's portfolio value rose 166% quarter-over-quarter to $473M.

Based on Foresite Capital Management II's 13F filing for Q3 2019, filed 13 Nov 2019.